Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

6.480 +0.960 (+17.39%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 210,647,810
Open 6.540
Bid (Size) 6.500 (2,000)
Ask (Size) 6.530 (100)
Prev. Close 5.520
Today's Range 6.080 - 7.980
52wk Range 1.830 - 7.980
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer ↗
On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans. 
Via The Motley Fool
Topics Stocks
Which stocks are most active on Tuesday? ↗
Via Chartmill

Performance

YTD
+220.8%
+220.8%
1 Month
+185.5%
+185.5%
3 Month
+164.5%
+164.5%
6 Month
+141.8%
+141.8%
1 Year
+101.2%
+101.2%

More News

Read More
IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing ↗
Via Stocktwits
News headline image
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
From ImmunityBio, Inc.
Via Business Wire
Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today ↗
Via Stocktwits
IBRX Stock Continues Rally — What’s Driving The Optimism Today? ↗
Via Stocktwits
IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval ↗
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Slide As Trump Ramps Up Greenland Threats: Why NFLX, CRML, TSLA, VERO, SRXH Are On Traders' Radar Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Why Is ImmunityBio Stock Back In Retail Spotlight Today? ↗
Via Stocktwits
Nasdaq, S&P 500 Futures Slide On Greenland Tensions: Why NVDA, MU, IBRX, CRML And VERO Are On Traders’ Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year ↗
Via The Motley Fool
Topics Stocks
Which stocks are experiencing notable movement on Friday? ↗
Via Chartmill
News headline image
Why ImmunityBio Stock Is Skyrocketing Again Today ↗
Via The Motley Fool
Curious about the most active stocks on Friday? ↗
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
From ImmunityBio, Inc.
Via Business Wire
News headline image
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% ↗
Via The Motley Fool
Topics Earnings Stocks
Thursday's session: top gainers and losers ↗
Via Chartmill
Which stocks are moving on Thursday? ↗
Via Chartmill
News headline image
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
From ImmunityBio, Inc.
Via Business Wire
News headline image
MAGA SmallCaps Watchlist: ROLR, SURG, IBRX, BNAI, NDRA – January 2026 Focus
Via AB Newswire
Topics Derivatives
News headline image
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
From USA News Group
Via GlobeNewswire
News headline image
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
From ImmunityBio
Via Business Wire

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?
Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
What exchange does ImmunityBio, Inc. - Common Stock trade on?
ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
What is the current price of ImmunityBio, Inc. - Common Stock?
The current price of ImmunityBio, Inc. - Common Stock is 6.480
When was ImmunityBio, Inc. - Common Stock last traded?
The last trade of ImmunityBio, Inc. - Common Stock was at 01/20/26 04:00 PM ET
What is the market capitalization of ImmunityBio, Inc. - Common Stock?
The market capitalization of ImmunityBio, Inc. - Common Stock is 2.53B
How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
ImmunityBio, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.